Elacytarabine: Additional Phase II data

Data from 46 evaluable patients with early-stage AML who have failed cytarabine-containing first-line treatment in the open-label, international Phase II CP4055-205 trial showed that 1,000 mg/m 2/day elacytarabine given as a continuous IV infusion on days 1-5 of a 21-day cycle plus idarubicin produced a CR/CRi rate, the primary endpoint, of 43.5% at a median follow-up of 34 weeks. Additionally, 6 patients achieved a partial response. The trial enrolled 51 patients. Data were presented at the American Society of Hematology meeting in Atlanta. ...